Overview

Effects of Glucagon Like Peptide-1 on No-reflow

Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
0
Participant gender:
All
Summary
The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Chen Wei Ren, MD
Treatments:
Glucagon
Glucagon-Like Peptide 1
Liraglutide
Criteria
Inclusion Criteria:

Patients with ST-segment elevation myocardial infarction were eligible for the study.

Exclusion Criteria:

Patients were excluded for the following reasons: unconscious at presentation; had
cardiogenic shock, hypoglycaemia, or diabetic ketoacidosis; had a history of myocardial
infarction, stent thrombosis, or renal insufficiency; or had previously undergone coronary
artery bypass surgery.